125 related articles for article (PubMed ID: 8372881)
1. Mutation of the p53 tumor-suppressor gene is not a feature of endometrial hyperplasias.
Kohler MF; Nishii H; Humphrey PA; Saski H; Marks J; Bast RC; Clarke-Pearson DL; Boyd J; Berchuck A
Am J Obstet Gynecol; 1993 Sep; 169(3):690-4. PubMed ID: 8372881
[TBL] [Abstract][Full Text] [Related]
2. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium.
Enomoto T; Fujita M; Inoue M; Rice JM; Nakajima R; Tanizawa O; Nomura T
Cancer Res; 1993 Apr; 53(8):1883-8. PubMed ID: 8385572
[TBL] [Abstract][Full Text] [Related]
3. Mutational analysis of the PTEN gene in endometrial carcinoma and hyperplasia.
Sun H; Enomoto T; Fujita M; Wada H; Yoshino K; Ozaki K; Nakamura T; Murata Y
Am J Clin Pathol; 2001 Jan; 115(1):32-8. PubMed ID: 11190805
[TBL] [Abstract][Full Text] [Related]
4. Bax, Bcl-2, and p53 expression in endometrial cancer.
Sakuragi N; Salah-eldin AE; Watari H; Itoh T; Inoue S; Moriuchi T; Fujimoto S
Gynecol Oncol; 2002 Sep; 86(3):288-96. PubMed ID: 12217750
[TBL] [Abstract][Full Text] [Related]
5. Detection of p53 gene mutations in human ovarian and endometrial cancers by polymerase chain reaction-single strand conformation polymorphism analysis.
Naito M; Satake M; Sakai E; Hirano Y; Tsuchida N; Kanzaki H; Ito Y; Mori T
Jpn J Cancer Res; 1992 Oct; 83(10):1030-6. PubMed ID: 1333465
[TBL] [Abstract][Full Text] [Related]
6. Alteration of the p53 tumor suppressor gene and activation of c-K-ras-2 protooncogene in endometrial adenocarcinoma from Colorado.
Enomoto T; Fujita M; Inoue M; Nomura T; Shroyer KR
Am J Clin Pathol; 1995 Feb; 103(2):224-30. PubMed ID: 7856567
[TBL] [Abstract][Full Text] [Related]
7. Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias.
Maxwell GL; Risinger JI; Gumbs C; Shaw H; Bentley RC; Barrett JC; Berchuck A; Futreal PA
Cancer Res; 1998 Jun; 58(12):2500-3. PubMed ID: 9635567
[TBL] [Abstract][Full Text] [Related]
8. BRAF mutation in endometrial carcinoma and hyperplasia: correlation with KRAS and p53 mutations and mismatch repair protein expression.
Feng YZ; Shiozawa T; Miyamoto T; Kashima H; Kurai M; Suzuki A; Konishi I
Clin Cancer Res; 2005 Sep; 11(17):6133-8. PubMed ID: 16144912
[TBL] [Abstract][Full Text] [Related]
9. Mutations of the KRAS oncogene in endometrial hyperplasia and carcinoma.
Dobrzycka B; Terlikowski SJ; Mazurek A; Kowalczuk O; Niklińska W; Chyczewski L; Kulikowski M
Folia Histochem Cytobiol; 2009; 47(1):65-8. PubMed ID: 19419940
[TBL] [Abstract][Full Text] [Related]
10. Assessment of the quality and frequency of mutations occurrence in PTEN gene in endometrial carcinomas and hyperplasias.
Konopka B; Paszko Z; Janiec-Jankowska A; Goluda M
Cancer Lett; 2002 Apr; 178(1):43-51. PubMed ID: 11849740
[TBL] [Abstract][Full Text] [Related]
11. Mutation and allelic loss of the p53 gene in endometrial carcinoma. Incidence and outcome in 92 surgical patients.
Kihana T; Hamada K; Inoue Y; Yano N; Iketani H; Murao S; Ukita M; Matsuura S
Cancer; 1995 Jul; 76(1):72-8. PubMed ID: 8630879
[TBL] [Abstract][Full Text] [Related]
12. Molecular analysis of endometrial hyperplasia in HNPCC-suspicious patients may predict progression to endometrial carcinoma.
Sutter C; Dallenbach-Hellweg G; Schmidt D; Baehring J; Bielau S; von Knebel Doeberitz M; Gebert J
Int J Gynecol Pathol; 2004 Jan; 23(1):18-25. PubMed ID: 14668545
[TBL] [Abstract][Full Text] [Related]
13. Involvement of p53 gene mutations in human endometrial carcinomas.
Honda T; Kato H; Imamura T; Gima T; Nishida J; Sasaki M; Hoshi K; Sato A; Wake N
Int J Cancer; 1993 Apr; 53(6):963-7. PubMed ID: 8473053
[TBL] [Abstract][Full Text] [Related]
14. Clonal analysis and mutations in the PTEN and the K-ras genes in endometrial hyperplasia.
Sun H; Enomoto T; Shroyer KR; Ozaki K; Fujita M; Ueda Y; Nakashima R; Kuragaki C; Ueda G; Murata Y
Diagn Mol Pathol; 2002 Dec; 11(4):204-11. PubMed ID: 12459636
[TBL] [Abstract][Full Text] [Related]
15. p53 gene mutations in human endometrial carcinoma.
Risinger JI; Dent GA; Ignar-Trowbridge D; McLachlan JA; Tsao MS; Senterman M; Boyd J
Mol Carcinog; 1992; 5(4):250-3. PubMed ID: 1497800
[TBL] [Abstract][Full Text] [Related]
16. PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumors.
Konopka B; Janiec-Jankowska A; Kwiatkowska E; Najmoła U; Bidziński M; Olszewski W; Goluda C
Hum Pathol; 2011 Nov; 42(11):1710-9. PubMed ID: 21531001
[TBL] [Abstract][Full Text] [Related]
17. [Genetic alterations and transformations in development and establishment of uterine endometrial carcinomas].
Inoue M
Nihon Sanka Fujinka Gakkai Zasshi; 1993 Aug; 45(8):751-62. PubMed ID: 8371006
[TBL] [Abstract][Full Text] [Related]
18. Molecular basis of endometrial cancer.
Berchuck A; Boyd J
Cancer; 1995 Nov; 76(10 Suppl):2034-40. PubMed ID: 8634996
[TBL] [Abstract][Full Text] [Related]
19. K-ras mutations appear in the premalignant phase of both microsatellite stable and unstable endometrial carcinogenesis.
Mutter GL; Wada H; Faquin WC; Enomoto T
Mol Pathol; 1999 Oct; 52(5):257-62. PubMed ID: 10748874
[TBL] [Abstract][Full Text] [Related]
20. Cyclin E gene (CCNE) amplification and hCDC4 mutations in endometrial carcinoma.
Cassia R; Moreno-Bueno G; Rodríguez-Perales S; Hardisson D; Cigudosa JC; Palacios J
J Pathol; 2003 Dec; 201(4):589-95. PubMed ID: 14648662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
